Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pimavanserin - ACADIA Pharmaceuticals

Drug Profile

Pimavanserin - ACADIA Pharmaceuticals

Alternative Names: ACP-103; BVF-048; Nuplazid; Pimavanserin tartrate

Latest Information Update: 15 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ACADIA Pharmaceuticals
  • Class Amides; Antidepressants; Antiparkinsonians; Antipsychotics; Behavioural disorder therapies; Fluorinated hydrocarbons; Piperidines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Serotonin 2A receptor antagonists; Serotonin 2A receptor inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Psychotic disorders
  • Phase III Major depressive disorder; Schizophrenia
  • Phase II/III Behavioural disorders
  • Phase II Agitation; Insomnia
  • No development reported Psychiatric disorders
  • Discontinued Drug-induced akathisia; Drug-induced dyskinesia

Most Recent Events

  • 11 Mar 2024 Efficacy and adverse events data from a phase III ADVANCE-2 trial in Schizophrenia released by Acadia Pharmaceuticals
  • 13 Dec 2023 US District Court for the District of Delaware granted summary judgment to Acadia Pharmaceuticals against MSN Laboratories, MSN Pharmaceuticals and other ANDA filers, confirming the validity of the NUPLAZID® '740 composition of matter patent in USA
  • 18 Sep 2023 ACADIA Pharmaceuticals updated the box warning for Pimavanserin
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top